Activities of the semisynthetic glycopeptide LY191145 against vancomycin- resistant enterococci and other gram-positive bacteria

T. I. Nicas, D. L. Mullen, J. E. Flokowitsch, D. A. Preston, N. J. Snyder, R. E. Stratford, R. D.G. Cooper

Research output: Contribution to journalArticle

45 Scopus citations


LY191145 is the prototype of a series of compounds with activities against vancomycin-resistant enterococci derived by modification of the glycopeptide antibiotic LY264826. LY191145 had MICs for vancomycin- and teicoplanin- resistant enterococci of ≤4 μg/ml for 50% of isolates and ≤16 μg/ml for 90% of isolates. Its MICs for vancomycin-resistant, teicoplanin-susceptible enterococci were 1 to 8 μg/ml. LY191145 retains the potent activities of its parent compound against staphylococci and streptococci. In vivo studies in a mouse infection model confirmed these activities. This compound indicates the potential of semisynthetic glycopeptides as agents against antibiotic- resistant gram-positive bacteria.

Original languageEnglish (US)
Pages (from-to)2585-2587
Number of pages3
JournalAntimicrobial Agents and Chemotherapy
Issue number11
StatePublished - Jan 1 1995


ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this